Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal ACYW135 conjugate vaccine
- Development stage
- Approved
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The meningococcal ACYW135 conjugate vaccine is a quadrivalent vaccine designed to provide active immunization against invasive disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. It works by inducing the body to produce antibodies against these bacterial serogroups. The "conjugate" formulation means that polysaccharide antigens from the bacterial capsule are chemically linked (conjugated) to a carrier protein (such as diphtheria toxoid), which enhances the immune response—especially in young children. This class of vaccines does not protect against serogroup B Neisseria meningitidis. The primary indication is prevention of invasive meningococcal disease in individuals from 2 months through 55 years of age[5][6][4].
- Brand names
- MenactraMenveoMenQuadfi
- Other names
- meningococcal A C Y and W-135 diphtheria conjugate vaccineMenACWY vaccinequadrivalent meningococcal conjugate vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal ACYW135 conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal ACYW135 conjugate vaccine.